1. Home
  2. VRAX vs ADXN Comparison

VRAX vs ADXN Comparison

Compare VRAX & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRAX
  • ADXN
  • Stock Information
  • Founded
  • VRAX 2013
  • ADXN 2002
  • Country
  • VRAX United Kingdom
  • ADXN Switzerland
  • Employees
  • VRAX N/A
  • ADXN N/A
  • Industry
  • VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • ADXN Biotechnology: Pharmaceutical Preparations
  • Sector
  • VRAX Health Care
  • ADXN Health Care
  • Exchange
  • VRAX Nasdaq
  • ADXN Nasdaq
  • Market Cap
  • VRAX 7.3M
  • ADXN 8.0M
  • IPO Year
  • VRAX 2022
  • ADXN N/A
  • Fundamental
  • Price
  • VRAX $1.66
  • ADXN $7.59
  • Analyst Decision
  • VRAX
  • ADXN Strong Buy
  • Analyst Count
  • VRAX 0
  • ADXN 1
  • Target Price
  • VRAX N/A
  • ADXN $30.00
  • AVG Volume (30 Days)
  • VRAX 256.7K
  • ADXN 24.6K
  • Earning Date
  • VRAX 02-05-2025
  • ADXN 03-24-2025
  • Dividend Yield
  • VRAX N/A
  • ADXN N/A
  • EPS Growth
  • VRAX N/A
  • ADXN N/A
  • EPS
  • VRAX N/A
  • ADXN 0.06
  • Revenue
  • VRAX $84,872.00
  • ADXN $701,260.00
  • Revenue This Year
  • VRAX $5,169.18
  • ADXN N/A
  • Revenue Next Year
  • VRAX $66.97
  • ADXN N/A
  • P/E Ratio
  • VRAX N/A
  • ADXN $1.04
  • Revenue Growth
  • VRAX 7.03
  • ADXN N/A
  • 52 Week Low
  • VRAX $0.60
  • ADXN $6.81
  • 52 Week High
  • VRAX $9.00
  • ADXN $27.90
  • Technical
  • Relative Strength Index (RSI)
  • VRAX 42.25
  • ADXN 48.97
  • Support Level
  • VRAX $1.56
  • ADXN $7.20
  • Resistance Level
  • VRAX $1.86
  • ADXN $8.04
  • Average True Range (ATR)
  • VRAX 0.19
  • ADXN 0.51
  • MACD
  • VRAX -0.04
  • ADXN 0.00
  • Stochastic Oscillator
  • VRAX 26.31
  • ADXN 47.95

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.

About ADXN Addex Therapeutics Ltd

Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.

Share on Social Networks: